Innovative CKD management: AstraZeneca’s Zibotentan/Dapagliflozin advances to Phase III

Recent findings from the ZENITH-CKD Phase IIb trial, conducted by AstraZeneca, have demonstrated a significant decrease in albuminuria among CKD patients treated with a combination ... Read More